Acura Pharmaceuticals Inc. (NASDAQ:ACUR) announced Thursday that it has entered into a Settlement Agreement with Ranbaxy Inc. to dismiss, without prejudice, its patent infringement action pending against Ranbaxy in the United States District Court for the District of Delaware. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) weekly performance is -9.56%. On last trading day company shares ended up $1.23. Analysts mean target price for the company is $2.25. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) distance from 50-day simple moving average (SMA50) is -18.81%.
As previously disclosed on a Current Report on Form 8-K filed January 4, 2013, Adamis Pharmaceuticals Corporation entered into a convertible promissory note with Robert Noel Robinson in an aggregate principal amount of $600,000. The Note was initially convertible into shares of the Company’s common stock at any time at the discretion of the Lender at an initial conversion price per share of $9.35, giving effect to the Company’s 1-for-17 reverse stock split of the outstanding common stock effected in December 2013. Effective June 25, 2013, the Company and the Lender entered into a Consent, Waiver and Amendment Regarding Convertible Promissory Note which, among other things, amended the maturity date of the Note to be March 26, 2014. Effective March 26, 2014, the Company and the Lender entered into an amendment to the Notes pursuant to which the maturity date of the Note was amended to be June 30, 2014. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares advanced 4.21% in last trading session and ended the day on $6.19. ADMP return on assets is -259.60%.Adamis Pharmaceuticals Corp (NASDAQ:ADMP) quarterly performance is -2.67%.
Zacks reissued their neutral rating on shares of Alkermes Plc (NASDAQ:ALKS) in a research report sent to investors on Friday morning, StockRatingsNetwork.com reports. The firm currently has a $50.00 price target on the stock. Alkermes Plc (NASDAQ:ALKS) shares moved down -1.63% in last trading session and was closed at $44.13, while trading in range of $43.00 – $45.26. Alkermes Plc (NASDAQ:ALKS) year to date (YTD) performance is 8.53%.
Bio-Path Holdings Inc. (NASDAQ:BPTH) Net loss for the year 2013 was $(3,266,013), compared to a Net Loss of $(2,582,537) for the year 2012. Bio-Path Holdings Inc. (NASDAQ:BPTH) ended the last trading day at $2.65. Company weekly volatility is calculated as 9.00% and price to cash ratio as 65.70.Bio-Path Holdings Inc. (NASDAQ:BPTH) showed a positive weekly performance of 8.61%.
Leave a Reply